The American Journal of Managed Care (10/9, Steinzor) reports a study found that “a self-guided smartphone app designed for individuals with intellectual disabilities (IDs) significantly reduced depressive symptoms and improved self-esteem and quality of life.” For the study, adults with IDs and depressive symptoms “were randomly assigned to either an intervention group using a self-help smartphone app or a waiting list control group. The app was based primarily on cognitive behavioral therapy techniques. Both groups continued receiving their usual care, which could include psychosocial support and general health services.” In intention-to-treat analyses, researchers observed that “participants in the intervention group experienced a greater reduction in depressive symptoms compared with the control group. The intervention group also showed significant improvements in quality of life and self-esteem, with the latter demonstrating a large effect size. Of the 99 participants enrolled, 92 completed the postintervention assessment, and participants reported high satisfaction with the app.” The study was published in JAMA Network Open.

Related Links:

— “Smartphone App Reduces Depression in Adults With Intellectual Disabilities,”Pearl Steinzor, The American Journal of Managed Care , October 9, 2025

MedPage Today (10/8, Firth) reports a study found that “cannabis use increased among people with psychosis after states legalized the substance for recreational use.” Researchers observed that “in states where recreational cannabis was legalized, 30-day cannabis use increased by 9.53 percentage points among people with psychosis.” This increase “was well above the 3.3-percentage point increase in past-month cannabis use among the general population observed in a recent study. Sensitivity analyses in the current study showed no significant increase in cannabis use before cannabis retail outlets opened. Weekly use did not significantly change.” The study was published in JAMA Psychiatry.

Related Links:

— MedPage Today (requires login and subscription)

Reuters (10/8, Stempel) reports New York City on Wednesday “filed a new lawsuit accusing Facebook, Google, Snapchat, TikTok and other online platforms of fueling a mental health crisis among children by addicting them to social media.” The complaint filed in “Manhattan federal court seeks damages from Facebook and Instagram owner Meta Platforms, Google and YouTube owner Alphabet, Snapchat owner Snap and TikTok owner ByteDance. It accuses the defendants of gross negligence and causing a public nuisance.” The suit alleges the companies designed their platforms to “exploit the psychology and neurophysiology of youth,” and drive compulsive use in pursuit of profit. According to Reuters, NYC “joined other governments, school districts and individuals pursuing approximately 2,050 similar lawsuits, in nationwide litigation in the Oakland, California, federal court.”

Related Links:

— “New York City sues social media companies for allegedly addicting children,”Jonathan Stempel, Reuters, October 8, 2025

Managed Healthcare Executive (10/7, Lutton) reports, “Older adults living with HIV are prescribed opioids at a higher rate and are more likely to develop opioid use disorder when compared with the general population, according to” research. Investigators “analyzed prescription and medical records of more than 650,000 Medicare beneficiaries with Part D coverage between 2008 and 2021.” The researchers “found that more than 1 in 3 (35%) of older adults with HIV received at least one opioid prescription per year during this time, while 28% of older adults without HIV received at least one opioid prescription per year.” Meanwhile, “5% of people with HIV received overlapping opioid prescriptions for more than 7 consecutive days, while only 4% of people without HIV did.” Additionally, “people living with HIV were…more likely to receive prescriptions greater than 120 mg (3%) than people without HIV (2%).” The findings were published in The Lancet Primary Care.

Related Links:

— “Opioid Prescriptions, Addiction More Common in Older HIV Patients,”Logan Lutton, Managed Healthcare Executive, October 7, 2025

Managed Healthcare Executive (10/7, Cox) reports, “All-cause mortality rates are more than three-fold higher in patients with schizophrenia, including a three-fold increased risk of death from Type 2 diabetes and a two-fold increased risk of death from cardiovascular disease,” but research “published in JAMA Psychiatry provides strong evidence that semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA) that is given once a week, may help control metabolic risk factors in patients who are at high risk.” Investigators “evaluated semaglutide in adults with schizophrenia and prediabetes who” had overweight or obesity “and who were prescribed second-generation antipsychotics.” The investigators “found that semaglutide significantly improved both glycemic control and body weight.” Meanwhile, “from a quality-of-life standpoint, semaglutide substantially enhanced physical quality of life.”

Related Links:

— “Semaglutide as a Dual Solution for Psychiatric and Metabolic Care,” Andrew Cox, Managed Healthcare Executive, October 7, 2025